12:00 AM
 | 
Oct 15, 2001
 |  BioCentury  |  Strategy

Contract muddle clears way for Tanox

In granting Tanox Inc. clear rights to one of its two most advanced proprietary compounds, a U.S. federal court judge last week provided an object lesson to would-be partners and their lawyers about sloppy contract writing.

Marilyn Hall Patel, chief judge of the U.S. District Court for the Northern District of California, last week issued a summary judgement in favor of TNOX (Houston, Texas) in a suit brought by Genentech Inc. (DNA, South San Francisco, Calif.) and Novartis AG (NVS; SWX:NOVN, Basel, Switzerland).

The three companies have been collaborating to develop anti-IgE antibodies under a 1996 pact that settled cross-actions between the then-competitors in the anti-IgE space, allowing the...

Read the full 538 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >